NFKB1 and breast carcinoma: On the other hand, although doxorubicin/daunorubicin also induces the phosphorylation and degradation of IκBα and increases the DNA-binding activity of NF-κB in osteosarcoma and breast cancer cells[26,27], yet they repress the NF-κB reporter activity and the expression of the NF-κB-regulated anti-apoptosis genes.